MeiraGTx adds Alan M. Sebulsky, former Adage Capital manager, to board
The genetic medicines company named Sebulsky a Class I director effective September 23, 2026, with a term running until the 2028 annual meeting.
MeiraGTx Holdings plc disclosed in an 8-K that its board, acting on the recommendation of its Nominating and Corporate Governance Committee, added Alan M. Sebulsky as a Class I director on September 22, 2026, effective September 23, 2026. His term runs until the company's 2028 annual shareholder meeting, when Class I directors face re-election, or until a successor is named.1 He will also serve on the Science and Technology Committee.1
Sebulsky's background is in healthcare investing. He spent the past 14 years as a Partner and Portfolio Manager at Adage Capital Management, where he led a team overseeing a diversified biopharmaceutical portfolio exceeding $2 billion in assets.1 Before that, he founded Apothecary Capital, a healthcare and biopharmaceutical asset management firm, and restarted it in April 2026, where he currently serves as Managing Member.1
His board history includes both public and private companies. He currently sits on the board of Parabilis Medicines, Inc., and has previously served on the boards and audit committees of Jazz Pharmaceuticals and Arrow International, along with three private healthcare companies backed by Apothecary Capital.1
Academically, he holds an M.S. in finance and a B.B.A. in finance and economics, both from the University of Wisconsin–Madison.1
On compensation and governance terms, the filing states Sebulsky will be eligible for pay under the company's standard Non-Employee Director Compensation Program.1 The company also noted he was not selected under any arrangement or understanding with another party, and there are no related party transactions between him and the company.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.